​

X4 Pharmaceuticals (XFOR) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

X4 Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$2.56M

Latest Revenue (Q)

$1.76M

Main Segment (Y)

Product Returns

X4 Pharmaceuticals Revenue by Period

X4 Pharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$2.56M100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31--100.00%
2020-12-31$3.00M100.00%
2019-12-31--100.00%
2018-12-31$3.50M100.00%
2017-12-31-100.00%
2016-12-31-100.00%
2015-12-31--

X4 Pharmaceuticals generated $2.56M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

X4 Pharmaceuticals Revenue by Quarter

DateRevenueChange
2025-09-30$1.76M-10.54%
2025-06-30$1.97M-93.15%
2025-03-31$28.81M1908.86%
2024-12-31$1.43M156.07%
2024-09-30$560.00K-0.53%
2024-06-30$563.00K100.00%
2024-03-31--100.00%
2023-12-31$3.06M100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30--100.00%
2020-03-31$3.00M100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31--100.00%
2018-12-31$3.50M100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31-100.00%
2017-09-30-100.00%
2017-06-30-100.00%
2016-12-31--

X4 Pharmaceuticals generated $1.76M in revenue during Q3 2025, up -10.54% compared to the previous quarter, and up 313.50% compared to the same period a year ago.

X4 Pharmaceuticals Revenue Breakdown

X4 Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
Product Returns$11.00K

X4 Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product Returns (100.00%).

Quarterly Revenue by Product

Product/ServiceSep 25Jun 25Mar 25Jun 24
License and Other Revenue$199.00K$229.00K$27.86M-
Product$4.25M$2.69M$942.00K-
Product Returns---$92.00K

X4 Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Product (95.53%), and License and Other Revenue (4.47%).

X4 Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
KPTIKaryopharm Therapeutics$145.24M$44.04M
MRSNMersana Therapeutics$40.50M$11.01M
FGENFibroGen$29.62M$1.08M
XFORX4 Pharmaceuticals$2.56M$1.76M
INMBINmune Bio$14.00K-
OKUROnKure Therapeutics--
KZRKezar Life Sciences--
ALGSAligos Therapeutics-$965.00K
SNTISenti Biosciences--
SKYESkye Bioscience--
TPSTTempest Therapeutics--

XFOR Revenue FAQ

What is X4 Pharmaceuticals’s yearly revenue?

X4 Pharmaceuticals's yearly revenue for 2024 was $2.56M, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. XFOR's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is X4 Pharmaceuticals’s quarterly revenue?

X4 Pharmaceuticals's quarterly revenue for Q3 2025 was $1.76M, a -10.54% decrease from the previous quarter (Q2 2025), and a 215.18% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $1.97M, a -93.15% decrease from the previous quarter (Q1 2025), and a 250.44% increase year-over-year (Q2 2024). XFOR's quarterly revenue for Q1 2025 was $28.81M, a 1908.86% increase from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024).

What is X4 Pharmaceuticals’s revenue growth rate?

X4 Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was -14.77%.

What are X4 Pharmaceuticals’s revenue streams?

X4 Pharmaceuticals's revenue streams in c 24 are Product Returns

What is X4 Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of X4 Pharmaceuticals was Product Returns. This segment made a revenue of $11K, representing 100.00% of the company's total revenue.